Research Summary

I am a physician-scientist whose research program focuses on hematopoietic growth control, genetic mechanisms underlying leukemogenesis, aberrant Ras signaling in human developmental disorders and cancer, mouse cancer modeling, and molecular therapeutics. I served as Director of the UCSF Medical Scientist Training Program (MSTP) from 2006-2012. I have been a research mentor for medical students, graduate students, and post-doctoral scholars, including six post-doctoral scholars who received “K” series awards from the NCI.

Research Funding

  • September 1, 2015 - August 31, 2026 - Developmental and HyperActive Ras Tumor SPORE , Multiple Principal Investigator . Sponsor: NIH, Sponsor Award ID: U54CA196519
  • April 1, 2015 - March 31, 2026 - Selectively Targeting Oncogenic NRAS in Cancer , Principal Investigtor . Sponsor: NIH, Sponsor Award ID: R01CA193994
  • February 15, 2022 - February 14, 2024 - Co-targeting Raf and MEK in Pediatric Acute Myeloid Leukemia , Principal Investigator . Sponsor: Cookies for Kids Cancer Foundation, Sponsor Award ID: Research Graant

Education

Williams College, Williamstown, MA, A.B., 1976, Biology, Liberal Arts
Cornell University, New York, NY, M.D., 1979, Medicine
University of Texas Southwestern, Dallas, TX, Resident, 1982, Pediatrics
University of California, San Francisco (UCSF), Postdoctoral, 1988, Hematology/Oncology

Honors & Awards

  • 1992
    Winner, Navy Academic Medicine Research Competition
  • 1993
    Nycomed Research Award of the International Society for Pediatric Oncology (SIOP)
  • 1994
    Ross Outstanding Young Investigator Award, Western Society for Pediatric Research
  • 1998
    American Academy of Pediatrics Award for Excellence in Pediatric Research
  • 2000
    Roma and Marvin Auerback Distinguished Professor of Pediatric Molecular Oncology, UCSF
  • 2004
    Samuel Rosenthal Prize for Excellence in Academic Pediatrics
  • 2006
    National Cancer Institute MERIT Award
  • 2010
    American Association of Physicians
  • 2010
    American Cancer Society Research Professorship
  • 2016
    Team Science Research Award, Children's Tumor Foundation
  • 2019
    Society of Memorial Sloan Kettering Research Prize
  • 2020
    UCSF Faculty Research Lecture in Basic Sciences

Selected Publications

  1. Levinson AL, Tjoa K, Huang B, Meyer LK, Kim MO, Brady SW, Zhang J, Shannon K, Wandler AM. Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL. Blood Adv. 2023 07 25; 7(14):3479-3484.  View on PubMed
  2. Suciu RM, Luvaga IK, Hazeen A, Weerasooriya C, Richardson SK, Firestone AJ, Shannon K, Howell AR, Cravatt BF. Chemical proteomic analysis of palmostatin beta-lactone analogs that affect N-Ras palmitoylation. Bioorg Med Chem Lett. 2021 12 01; 53:128414.  View on PubMed
  3. Remsberg JR, Suciu RM, Zambetti NA, Hanigan TW, Firestone AJ, Inguva A, Long A, Ngo N, Lum KM, Henry CL, Richardson SK, Predovic M, Huang B, Dix MM, Howell AR, Niphakis MJ, Shannon K, Cravatt BF. ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth. Nat Chem Biol. 2021 08; 17(8):856-864.  View on PubMed
  4. Wong JC, Perez-Mancera PA, Huang TQ, Kim J, Grego-Bessa J, Del Pilar Alzamora M, Kogan SC, Sharir A, Keefe SH, Morales CE, Schanze D, Castel P, Hirose K, Huang GN, Zenker M, Sheppard D, Klein OD, Tuveson DA, Braun BS, Shannon K. KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice. JCI Insight. 2020 11 05; 5(21).  View on PubMed
  5. Shannon K, Link DC. Soil and Seed: Coconspirators in Therapy-Induced Myeloid Neoplasms. Blood Cancer Discov. 2020 07; 1(1):10-12.  View on PubMed
  6. Zambetti NA, Firestone AJ, Remsberg JR, Huang BJ, Wong JC, Long AM, Predovic M, Suciu RM, Inguva A, Kogan SC, Haigis KM, Cravatt BF, Shannon K. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice. Blood. 2020 05 14; 135(20):1772-1782.  View on PubMed
  7. Wandler AM, Huang BJ, Craig JW, Hayes K, Yan H, Meyer LK, Scacchetti A, Monsalve G, Dail M, Li Q, Wong JC, Weinberg O, Hasserjian RP, Kogan SC, Jonsson P, Yamamoto K, Sampath D, Nakitandwe J, Downing JR, Zhang J, Aster JC, Taylor BS, Shannon K. Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2020 08; 34(8):2025-2037.  View on PubMed
  8. Meyer LK, Huang BJ, Delgado-Martin C, Roy RP, Hechmer A, Wandler AM, Vincent TL, Fortina P, Olshen AB, Wood BL, Horton TM, Shannon KM, Teachey DT, Hermiston ML. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest. 2020 02 03; 130(2):863-876.  View on PubMed
  9. Bhatia S, Chen Y, Wong FL, Hageman L, Smith K, Korf B, Cannon A, Leidy DJ, Paz A, Andress JE, Friedman GK, Metrock K, Neglia JP, Arnold M, Turcotte LM, de Blank P, Leisenring W, Armstrong GT, Robison LL, Clapp DW, Shannon K, Nakamura JL, Fisher MJ. Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1. J Clin Oncol. 2019 11 10; 37(32):3050-3058.  View on PubMed
  10. Meyer LK, Delgado-Martin C, Maude SL, Shannon KM, Teachey DT, Hermiston ML. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. PLoS One. 2019; 14(7):e0220026.  View on PubMed
  11. Huang BJ, Wandler AM, Meyer LK, Dail M, Daemen A, Sampath D, Li Q, Wang X, Wong JC, Nakitandwe J, Downing JR, Zhang J, Taylor BS, Shannon K. Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias. PLoS Genet. 2019 06; 15(6):e1008168.  View on PubMed
  12. Mues M, Karra L, Romero-Moya D, Wandler A, Hangauer MJ, Ksionda O, Thus Y, Lindenbergh M, Shannon K, McManus MT, Roose JP. High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions. Cell Rep. 2019 04 09; 27(2):631-647.e5.  View on PubMed
  13. Bielski CM, Donoghue MTA, Gadiya M, Hanrahan AJ, Won HH, Chang MT, Jonsson P, Penson AV, Gorelick A, Harris C, Schram AM, Syed A, Zehir A, Chapman PB, Hyman DM, Solit DB, Shannon K, Chandarlapaty S, Berger MF, Taylor BS. Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell. 2018 11 12; 34(5):852-862.e4.  View on PubMed
  14. Wong JC, Bryant V, Lamprecht T, Ma J, Walsh M, Schwartz J, Del Pilar Alzamora M, Mullighan CG, Loh ML, Ribeiro R, Downing JR, Carroll WL, Davis J, Gold S, Rogers PC, Israels S, Yanofsky R, Shannon K, Klco JM. Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. JCI Insight. 2018 07 26; 3(14).  View on PubMed
  15. Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, Pollyea DA, Smith CA, Jordan CT. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell. 2018 Jul 05; 23(1):86-100.e6.  View on PubMed
  16. Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, Ducker GS, Matlawska-Wasowska K, Shannon K, Shokat KM, Roose JP. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. PLoS One. 2018; 13(5):e0193849.  View on PubMed
  17. Wandler A, Shannon K. Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. Cold Spring Harb Perspect Med. 2018 04 02; 8(4).  View on PubMed
  18. Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K. A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res. 2017 11 01; 77(21):5706-5711.  View on PubMed
  19. Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K. KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. Cell. 2017 02 23; 168(5):817-829.e15.  View on PubMed
  20. Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017 Mar; 23(3):301-313.  View on PubMed

Go to UCSF Profiles, powered by CTSI